Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Hexarelin vs Tesamorelin
An educational, source-based comparison of Hexarelin and Tesamorelin — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic hexapeptide and potent GHS-R agonist. Stimulates GH release more strongly than GHRP-6 and shows cardioprotective signaling in preclinical ischemia-reperfusion models, partly independent of GH.
- GH release
- Cardiac ischemia-reperfusion (preclinical)
- Left ventricular function in animal models
- • Not FDA-approved.
- • Tachyphylaxis with prolonged use.
- • Prohibited by WADA.
A stabilized analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile endogenous GH and IGF-1 release. FDA-approved (Egrifta) for the reduction of excess abdominal visceral fat in HIV-infected patients with lipodystrophy.
- Visceral adipose tissue reduction (approved)
- Cognitive function in older adults (research)
- NAFLD / hepatic fat (research)
- • FDA-approved only for HIV-associated lipodystrophy.
- • May affect glucose tolerance; monitor in at-risk patients.
- • Requires physician oversight.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Early-stage research; conclusions are tentative.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Hexarelin | Hexarelin and the cardiovascular system | Cardiovascular Research | 2006 | Reviewed direct cardioprotective effects of hexarelin in animal models. |
| Tesamorelin | Tesamorelin for HIV-associated lipodystrophy | New England Journal of Medicine | 2007 | Phase 3 trials showing significant visceral fat reduction. |
| Tesamorelin | Tesamorelin and NAFLD in HIV | The Lancet HIV | 2019 | Reduced hepatic fat fraction in HIV-infected adults with NAFLD. |
Side-effect & safety grid
- Not FDA-approved.
- Tachyphylaxis with prolonged use.
- Prohibited by WADA.
- FDA-approved only for HIV-associated lipodystrophy.
- May affect glucose tolerance; monitor in at-risk patients.
- Requires physician oversight.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Hexarelin vs Tesamorelin — Key differences
- Class: Hexarelin is classified as Growth Hormone Axis · Cardiac, while Tesamorelin is Growth Hormone Axis.
- Primary research focus: Hexarelin — gh release; Tesamorelin — visceral adipose tissue reduction (approved).
- Tag: Growth hormone vs Body composition.